Mutations in NRAS and KRAS were seen exclusively in B-ALL patients (22% and 17%, respectively), whereas none of these mutations were detected in blastoid-HGBL cases (both p < 0.05). This evidence concerns the gene NRAS and high grade B-cell lymphoma.